Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Alpelisib is the drug of choice for patients with PIK3CA-mutated breast cancer and offers new treatment hope for patients with advanced and metastatic breast cancer, especially tho···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：405
In 2022, Alpelisib received accelerated FDA approval for patients on the PIK3CA-associated overgrowth disease spectrum, particularly those adults and children over 2 years of age w···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：412
As the first oral small molecule drug for HR/HER2- and PIK3CA-mutated advanced breast cancer, Alpelisib effectively prolongs the progression-free survival of patients by inhibiting···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：349
In 2022, Alpelisib received accelerated FDA approval for the treatment of adults and children over 2 years of age on the PIK3CA-associated overgrowth disease spectrum, an expanded ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：369
Balversa is currently a new star in the field of anti-cancer, which is used orally to treat FGFR mutant tumors such as urothelial carcinoma, has extraordinary effects in the field ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：368
Alpelisib was approved by the FDA in 2019 as a PIK3CA kinase inhibitor in combination with fulvestrant, providing a new treatment option for patients with advanced breast cancer wi···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：399
Balversa is a new oral anti-cancer star on the market, showing excellent tumor suppression effects against FGFR mutant tumors such as urothelial carcinoma, but it has not yet been ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：335
Alpelisib was approved by the FDA in May 2019 for use in combination with fulvestrant to inhibit tumor progression in postmenopausal women and men with advanced breast cancer with ···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：416
As a PIK3CA kinase inhibitor, Alpelisib plays an important role in the relationship between the activation of the PI3K pathway and tumor drug resistance, especially in patients wit···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：374
Balversais an oral anti-cancer star targeting FGFR mutations, which has a significant inhibitory effect on tumors such as urothelial carcinoma, but it has not yet landed in the dom···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：427
Balversa is an oral anticancer drug that specializes in FGFR mutant tumors, such as urothelial carcinoma, and effectively inhibits tumor proliferation, but has not yet been introdu···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：404
Balversa is an oral anticancer drug used for the treatment of locally advanced or metastatic urothelial carcinoma, inhibiting FGFR activity to stop tumor growth, but it is not curr···【more】
Article source：Captain MedicineRelease date：2024-08-27Recommended：384
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
In recent years, Laos has gradually become a major global supply source for generic drugs, leveragin···【more】
Recommended：[list:visits]2026-22-07
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies ···【more】
Recommended：[list:visits]2026-21-07
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was···【more】
Recommended：[list:visits]2026-20-07
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was···【more】
Recommended：[list:visits]2026-17-07
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos'···【more】
Recommended：[list:visits]2026-16-07
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease pa···【more】
Recommended：[list:visits]2026-15-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
